Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jun 22;325(24):2457-2465.
doi: 10.1001/jama.2021.7152.

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Yoel Angel  1   2 , Avishay Spitzer  2   3   4 , Oryan Henig  2   5 , Esther Saiag  2   6 , Eli Sprecher  2   7   8 , Hagit Padova  2   9 , Ronen Ben-Ami  2   5
Affiliations
Observational Study

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Yoel Angel et al. JAMA. .

Abstract

Importance: Randomized clinical trials have provided estimates of the effectiveness of the BNT162b2 vaccine against symptomatic SARS-CoV-2 infection, but its effect on asymptomatic infections remains unclear.

Objective: To estimate the association of vaccination with the Pfizer-BioNTech BNT162b2 vaccine with symptomatic and asymptomatic SARS-CoV-2 infections among health care workers.

Design, setting, and participants: This was a single-center, retrospective cohort study conducted at a tertiary medical center in Tel Aviv, Israel. Data were collected on symptomatic and asymptomatic SARS-CoV-2 infections confirmed via polymerase chain reaction (PCR) tests in health care workers undergoing regular screening with nasopharyngeal swabs between December 20, 2020, and February 25, 2021. Logistic regression was used to calculate incidence rate ratios (IRRs) comparing the incidence of infection between fully vaccinated and unvaccinated participants, controlling for demographics and the number of PCR tests performed.

Exposures: Vaccination with the BNT162b2 vaccine vs unvaccinated status was ascertained from the employee health database. Full vaccination was defined as more than 7 days after receipt of the second vaccine dose.

Main outcomes and measures: The primary outcome was the regression-adjusted IRR for symptomatic and asymptomatic SARS-CoV-2 infection of fully vaccinated vs unvaccinated health care workers. The secondary outcomes included IRRs for partially vaccinated health care workers (days 7-28 after first dose) and for those considered as late fully vaccinated (>21 days after second dose).

Results: A total of 6710 health care workers (mean [SD] age, 44.3 [12.5] years; 4465 [66.5%] women) were followed up for a median period of 63 days; 5953 health care workers (88.7%) received at least 1 dose of the BNT162b2 vaccine, 5517 (82.2%) received 2 doses, and 757 (11.3%) were not vaccinated. Vaccination was associated with older age compared with those who were not vaccinated (mean age, 44.8 vs 40.7 years, respectively) and male sex (31.4% vs 17.7%). Symptomatic SARS-CoV-2 infection occurred in 8 fully vaccinated health care workers and 38 unvaccinated health care workers (incidence rate, 4.7 vs 149.8 per 100 000 person-days, respectively, adjusted IRR, 0.03 [95% CI, 0.01-0.06]). Asymptomatic SARS-CoV-2 infection occurred in 19 fully vaccinated health care workers and 17 unvaccinated health care workers (incidence rate, 11.3 vs 67.0 per 100 000 person-days, respectively, adjusted IRR, 0.14 [95% CI, 0.07-0.31]). The results were qualitatively unchanged by the propensity score sensitivity analysis.

Conclusions and relevance: Among health care workers at a single center in Tel Aviv, Israel, receipt of the BNT162b2 vaccine compared with no vaccine was associated with a significantly lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection more than 7 days after the second dose. Findings are limited by the observational design.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Angel reported receiving research grants from Pfizer outside the scope of this work. Dr Spitzer reported being partially supported by the Israeli Council for Higher Education via the Weizmann Data Science Research Center and by a research grant from Madame Olga Klein–Astrachan. Dr Ben-Ami reported receiving consulting fees from Pfizer, Gilead, and Merck Sharp & Dohme outside the scope of this work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Institutional Screening Policies, Vaccine Uptake in the Vaccinated Group, and the Daily Proportion of Vaccinated and Unvaccinated Participants Tested for SARS-CoV-2
PCR indicates polymerase chain reaction. aA detailed description of the study periods appears in the eMethods in the Supplement. bRegardless of vaccination status. cUnadjusted for propensity score. dAdjusted for propensity score.
Figure 2.
Figure 2.. Study Cohort Derivation Process
PCR indicates polymerase chain reaction.
Figure 3.
Figure 3.. Cumulative Incidence of SARS-CoV-2 Infection Among Vaccinated, Propensity Score–Matched Vaccinated, and Unvaccinated Participants Screened for SARS-CoV-2 Infection
Data are the cumulative incidence of symptomatic and asymptomatic SARS-CoV-2 cases after the first dose of the vaccine in the unvaccinated cohort (n = 757), in the original vaccinated cohort (n = 5953), and in the propensity score–matched vaccinated cohort (n = 2141). Additional information appears in eFigure 2 in the Supplement. aUnadjusted for propensity score.
See this image and copyright information in PMC

Comment in

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. US Food and Drug Agency . Emergency Use Authorization for Pfizer-BioNTech COVID-19 vaccine. Accessed February 25, 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise...
    1. Rosen B, Waitzberg R, Israeli A. Israel’s rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res. 2021;10(1):6. doi:10.1186/s13584-021-00440-6 - DOI - PMC - PubMed
    1. Israel Ministry of Health . Israeli COVID-19 dataset. Accessed March 22, 2021. https://data.gov.il/dataset/covid-19
    1. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus pandemic (COVID-19): our world in data. Accessed February 25, 2021. https://ourworldindata.org/coronavirus

Publication types